Search Results for:
-
NPS Reclaims Rights to 2 Drugs From Takeda in $50M Stock Deal
It has steadfastly continued with plans to seek approval in the U.S., proactively including a comprehensive risk evaluation and mitigation strategies plan with its planned new drug application submissionBy Catherine Shaffer | BioWorld Today | Wednesday, March 20, 2013 -
InSite Shares Gain on BromSite Phase III Data
The AzaSite Plus and DexaSite Phase III programs also are expected to report data this year, and InSite is not averse to filing three new drug applications on its ownBy Marie Powers | BioWorld Today | Wednesday, March 20, 2013 -
Committee to Scrutinize Titan's Implantable Buprenorphine
Titan submitted its new drug application for Probuphine to the FDA in October 2012 under the 505(b)(2) pathwayBy Catherine Shaffer | BioWorld Today | Wednesday, March 20, 2013 -
Other News To Note
QRxPharma Ltd., of Sydney, Australia, said the FDA set a PDUFA date of Aug. 26 for the resubmitted new drug application seeking approval of Moxduo, an immediate-release dual opioid pain therapy that combines morphine and oxycodoneBioWorld International | Wednesday, March 20, 2013 -
Dry-Eye Phase III Trial Enrolled, OphthaliX 'Wets' Oral Appetite
Slow enrollment and new data generated under a compassionate-use investigational new drug application led to the closure of the trial in January 2009By Randy Osborne | BioWorld Today | Tuesday, March 19, 2013 -
Clinic Roundup
The company submitted a supplemental new drug application in December to expand the use to all adults with IDA who have failed or could not tolerate oral iron treatment. (See BioWorld Today, July 1, 2009BioWorld Today | Monday, March 18, 2013 -
Other News To Note
Spectrum is assuming responsibility for the ongoing trial and will be responsible for filing a new drug application, expected in the first half of 2014...The company anticipates that 1 kg will be sufficient to complete the upcoming investigational new drug application-enabling animal toxicity studies and Phase I trialsBioWorld Today | Friday, March 15, 2013 -
Other News To Note
The company has also submitted new drug applications to the FDA for canagliflozin and for the fixed-dose combination therapyBioWorld International | Wednesday, March 13, 2013 -
Planning for Global Expansion, Cell Medica Recruits New CMO
investigational new drug applicationBy Nuala Moran | BioWorld International | Wednesday, March 13, 2013 -
As Ambit Eyes IPO, Astellas Drops FLT3 Partnership
Astellas exercised its right to terminate the program as part of the worldwide license agreement inked with Ambit in 2009. (See BioWorld Today, Dec. 21, 2009.) Over the next six months, the companies will work together to transfer management of ongoing clinical trials and their governing investigational new drug applications to Ambit, which will then regain all rights to the quizartinib clinical trial and development programBy Marie Powers | BioWorld Today | Wednesday, March 13, 2013 -
Aeterna Zentaris Slides on Perifosine Miss in Myeloma
The company is prepping for a new drug application filing for AEZS-130, a ghrelin agonist that has shown potential as an oral diagnostic test for adult growth hormone deficiencyBy Staff Reports | BioWorld Today | Tuesday, March 12, 2013 -
Cangrelor Steps Up to 'Platelet,' Hits Phase III Data Home Run
A new drug application is expected to be filed in the second quarter of this year, and Medicines intends to seek European approval before 2013 finishesBy Randy Osborne | BioWorld Today | Tuesday, March 12, 2013 -
Other News To Note
Acceptance of the questionnaire by the FDA allows Ampio or a pharmaceutical partner to file an investigational new drug application in the U.S...Assuming continued clinical success, Tris expects to file a new drug application in mid-2014BioWorld Today | Tuesday, March 12, 2013 -
IPO Queue Gains Two New Entries: Chimerix, Omthera
The company will allocate about $30 million to $35 million to development costs in preparation for a new drug application, to costs of increasing manufacturing capacity and validating manufacturing process, and to build commercial inventoryBy Catherine Shaffer | BioWorld Today | Tuesday, March 12, 2013 -
FDA Submissions, Approvals & Other Actions: February 2013
IND = Investigational new drug application...NDA = New drug applicationBioWorld Insight | Monday, March 11, 2013 -
Following Ravicti Win in UCD, Hyperion Seeks $59.7M for HE
A new drug application is expected later this yearBy Marie Powers | BioWorld Today | Monday, March 11, 2013 -
Companies Look to Capture Part of Growing Respiratory Market
In January the company completed a $287.5 million debt financing in preparation to make milestone payments to its partner GSK upon launch of their combination products developed under the two companies' 2002 collaboration around long-acting beta 2 agonists (LABAs) and bifunctional muscarinic antagonist-beta2 agonists (MABAs). (See BioWorld Today, Jan. 18, 2013.) Theravance may also be receiving positive vibes from a January PADAC recommendation that clinical data included in a new drugBy Peter Winter | BioWorld Insight | Monday, March 11, 2013 -
FDA Unveils Plan for Structured Benefit-Risk Assessment
Its use will be extended to efficacy supplements for new/expanded indications in fiscal 2016 and to all original new drug applications the following yearBy Mari Serebrov | BioWorld Today | Friday, March 8, 2013 -
Pharma: Other News To Note
The company has also submitted new drug applications to the FDA for canagliflozin and for the fixed-dose combination therapyBioWorld Today | Friday, March 8, 2013 -
Other News To Note
AMAG Pharmaceuticals Inc., of Lexington, Mass., said the FDA accepted for review its supplemental new drug application (sNDA) for Feraheme (ferumoxytol) injection for intravenous useBioWorld Today | Thursday, March 7, 2013
Category
Current Filters
- xdrug application
Related Keywords
Categories
- x BioWorld Today (7432)
- x BioWorld Insight (561)
- x BioWorld International (479)
- x Bio Perspectives (114)
- x State of the Industry Report (45)
- x BioWorld Snapshots (16)
- x Top 25 Drug Report (12)
- x BioWorld Genomics Review (12)
- x Biotech Innovations (11)
- x RNAi Report (2)
- x Market-Leading Biotech Drugs (2)
- x Executive Compensation Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.